Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Susu Xiao'er Zhike Granules for Cough in Children with Common Cold
NCT04457011Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Susu Xiao'er Zhike Granules in common cold (3 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Time to Resolution of cough and Resolution rate of cough. Started Sep 2020; status: completed.
02
Drugs
Susu Xiao'er Zhike Granules
03
Conditions
common cold
Beyond the preview
Go deeper on NCT04457011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457011.